SCHEMBL22424576

SCHEMBL22424576

COc1ccc(Cn2c(N)nc3c(c2=O)CCN(C=O)C3)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE5A O76074 1/20 0.44
▸ PDE4A P27815 1/20 0.44
▸ PDE4B Q07343 1/20 0.44
▸ PDE4C Q08493 1/20 0.44
▸ PDE4D Q08499 1/20 0.44
▸ PNP P00491 1/20 0.43
▸ CLPP Q16740 3/20 0.42
▸ ALDH1A1 P00352 3/20 0.39
▸ POLB P06746 1/20 0.39
▸ HTT P42858 1/20 0.39
▸ P2RX4 Q99571 1/20 0.38
▸ TYMS P04818 1/20 0.38
▸ DHFR P00374 1/20 0.38
▸ GABRA5 P31644 1/20 0.38
▸ TP53 P04637 1/20 0.38
▸ GAA P10253 2/20 0.37
▸ TDP1 Q9NUW8 1/20 0.37
▸ L3MBTL1 Q9Y468 1/20 0.37
▸ KDM4E B2RXH2 1/20 0.37
▸ GLA P06280 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28671519 0.82 CLPP (0.44) PDE5APDE4APDE4BPDE4CPDE4D
SCHEMBL22410754 0.79 P2RX3 (0.51) PDE5APDE4APDE4BPDE4CPDE4D
SCHEMBL22424057 0.78 PNP (0.48) PDE5APDE4APDE4BPDE4CPDE4D
SCHEMBL22424242 0.76 MAPT (0.44) ALDH1A1POLBHTTTP53GAA
SCHEMBL22424051 0.68 CLPP (0.39) CLPPALDH1A1POLBHTTTP53
SCHEMBL22746816 0.66 ALDH1A1 (0.41) CLPPALDH1A1POLBHTTGAA
SCHEMBL1573104 0.65 PNP (0.52) PDE5APDE4APDE4BPDE4CPDE4D
SCHEMBL17491168 0.65 SIGMAR1 (0.71) ALDH1A1POLBSIGMAR1LMNA
SCHEMBL1573111 0.65 PDE5A (0.51) PDE5APDE4APDE4BPDE4CPDE4D
SCHEMBL9242005 0.65 PNP (0.51) PDE5APDE4APDE4BPDE4CPDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020182990-A1 FUSED RING PYRIMIDONE DERIVATIVES FOR USE IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES Janssen Sciences Ireland Unlimited Company (IE) 2020-09-17 — — WO disclosed
Send feedback